US Patent Number
8481508
Publication Date
7-9-2013
Abstract
Provided are methods and compositions for the treatment or prevention of macular degeneration or other diseases or disorders associated with activation of TLR3. Administration of double stranded RNAs having a length of 22 nucleotides or less treats or prevents macular degeneration or other diseases or disorders associated with activation of TLR3 due to the ability of the RNAs to bind to but not activate TLR3. Furthermore, all double stranded RNAs (both targeted and non-targeted) of 22 nucleotides or less in length can bind to but not activate TLR3 and thereby treat or prevent such conditions. Also provided of a method for increasing the specificity of a desire siRNA target knockdown, the method comprising administering an amount of a target siRNA sufficient to knockdown a target gene and an amount of a double stranded RNA of 22 nucleotides or less which prevents the target siRNA from activating TLR3.
Assignees
University of Kentucky Research Foundation, Lexington, KY (US)
Application Number
12/918,548
Filing Date
02/20/2009
Recommended Citation
Ambati, Jayakrishna, "Ultra-Small RNAs as Toll-Like Receptor-3 Antagonists" (2013). Ophthalmology and Visual Science Faculty Patents. 2.
https://uknowledge.uky.edu/ophthalmology_patents/2
